Source: International Congress 2019 – CCC Pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ghirardo (Trieste, Italy). Hughes Stovin vasculitis: regression of pulmonary aneurisms and sustained remission with anti-TNF treatment. International Congress 2019 – CCC Pulmonary vascular diseases

Member's Comments

No comment yet.

Related content which might interest you: Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture Source: Eur Respir J 2009; 33: 666-669 Year: 2009 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Source: Eur Respir J 2009; 33: 371-379 Year: 2009 Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018 Year: 2019 Early outcomes of patients with systemic lupus erythematosus and antiphospholipid syndrome after pulmonary endarterectomy Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004 Early pulmonary hemodynamical changes in systemic sclerosis. A one-year follow-up Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis Source: Eur Respir J 2004; 24 : 708 Year: 2004 Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy Source: Eur Respir J 2014; 43: 1513-1515 Year: 2014 An autopsy case of pulmonary veno-occlusive disease refractory to imatinib Source: Eur Respir J 2011; 37: 968-970 Year: 2011 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Predictors of pulmonary artery hypertension in patients with systemic sclerosis Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: 496-504 Year: 2006 ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:E66 Year: 2016